Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Oncology Letters|March 21, 2018
Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysisBinbin Hu, Xiaojuan Zhou, Yongmei Liu, et al.
Environment International|August 22, 2024
Soil keystone viruses are regulators of ecosystem multifunctionalityPu Jia, Jie-Liang Liang, Jing-Li Lu, et al.
Molecular Ecology|December 29, 2020
A single nucleotide polymorphism variant located in the cis-regulatory region of the ABCG2 gene is associated with mallard egg colourHehe Liu, Jian Hu, Zhanbao Guo, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2020
Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung CancerLimei Yin, Jianxin Xue, Rui Li, et al.
Neuro-Oncology|February 23, 2026
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR-Mutant NSCLC Patients with Brain Metastases: A Phase I/II StudyMin Yu, Caini Chen Undergraduate, Youling Gong, et al.
Cancer Medicine|October 7, 2020
Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutionsTingyou Zhang, Yu Zhang, Lin Zhou, et al.
Nature Communications|April 23, 2026
Molecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptorsNour Aldin Kahlous, Maiju K Rinne, Xin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer PatientsXiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, et al.
Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.
Pageof 19